JP4444821B2 - 遺伝子組み換えによる新しい抗凝血性蛋白質 - Google Patents

遺伝子組み換えによる新しい抗凝血性蛋白質 Download PDF

Info

Publication number
JP4444821B2
JP4444821B2 JP2004510698A JP2004510698A JP4444821B2 JP 4444821 B2 JP4444821 B2 JP 4444821B2 JP 2004510698 A JP2004510698 A JP 2004510698A JP 2004510698 A JP2004510698 A JP 2004510698A JP 4444821 B2 JP4444821 B2 JP 4444821B2
Authority
JP
Japan
Prior art keywords
anv
seq
tfpi
factor
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2004510698A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005528124A5 (enExample
JP2005528124A (ja
Inventor
ツェ・チェイン・ウン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tze Chein Wun
Original Assignee
Tze Chein Wun
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tze Chein Wun filed Critical Tze Chein Wun
Publication of JP2005528124A publication Critical patent/JP2005528124A/ja
Publication of JP2005528124A5 publication Critical patent/JP2005528124A5/ja
Application granted granted Critical
Publication of JP4444821B2 publication Critical patent/JP4444821B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4721—Lipocortins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
    • C07K14/8114—Kunitz type inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Pulmonology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2004510698A 2002-06-06 2003-06-04 遺伝子組み換えによる新しい抗凝血性蛋白質 Expired - Fee Related JP4444821B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US38693202P 2002-06-06 2002-06-06
PCT/US2003/017442 WO2003103577A2 (en) 2002-06-06 2003-06-04 Novel recombinant anticoagulant proteins

Publications (3)

Publication Number Publication Date
JP2005528124A JP2005528124A (ja) 2005-09-22
JP2005528124A5 JP2005528124A5 (enExample) 2006-07-20
JP4444821B2 true JP4444821B2 (ja) 2010-03-31

Family

ID=29736237

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2004510698A Expired - Fee Related JP4444821B2 (ja) 2002-06-06 2003-06-04 遺伝子組み換えによる新しい抗凝血性蛋白質

Country Status (8)

Country Link
US (2) US7378393B2 (enExample)
EP (1) EP1509541B1 (enExample)
JP (1) JP4444821B2 (enExample)
CN (1) CN1659180B (enExample)
AT (1) ATE534658T1 (enExample)
AU (1) AU2003237351B2 (enExample)
CA (1) CA2486362A1 (enExample)
WO (1) WO2003103577A2 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7635680B2 (en) 2001-02-21 2009-12-22 Alavita Pharmaceuticals, Inc. Attenuation of reperfusion injury
US7635676B2 (en) 2001-02-21 2009-12-22 Alavita Pharmaccuticals, Inc. Modified annexin proteins and methods for their use in organ transplantation
US7671013B2 (en) * 2003-04-03 2010-03-02 Canadian Blood Services, Inc. Coagulation proteins, coagulation-anticoagulation protein complexes, derivatives thereof and their uses
CA2559167A1 (en) * 2004-03-11 2005-09-22 Alavita, Inc. Modified annexin proteins and methods for preventing thrombosis
US7511016B2 (en) * 2004-07-07 2009-03-31 Mosamedix B.V. Annexins, derivatives thereof, and annexin-cys variants, as well as therapeutic and diagnostic uses thereof
PL2234631T3 (pl) 2007-12-18 2013-03-29 Athera Biotechnologies Ab Związki i metody stosowane w terapii choroby naczyniowej
HUE044621T2 (hu) * 2008-02-22 2019-11-28 Annexin Pharmaceuticals Ab Vegyületek és eljárások resztenózis megelõzésére vagy kezelésére
CA2740557C (en) 2008-10-17 2020-04-14 London Health Sciences Centre Research Inc. Annexin and its use to treat inflammatory disorders
JP6200806B2 (ja) 2010-05-21 2017-09-20 メリマック ファーマシューティカルズ インコーポレーティッド 二重特異的融合タンパク質
CN115960249A (zh) 2015-10-02 2023-04-14 银溪制药股份有限公司 用于组织修复的双特异性治疗性蛋白质
BR102017005783A2 (pt) * 2017-03-21 2018-10-02 Fund Butantan processo de obtenção de esculptina e seus fragmentos, esculptina recombinante e seus usos
TW202146042A (zh) * 2020-03-06 2021-12-16 瑞典商阿斯特捷利康公司 用於治療動脈和靜脈血栓形成的協同且靶向的組成物
CN113956339B (zh) * 2021-10-28 2023-02-24 中国药科大学 宽体金线蛭抗凝血因子XIa多肽及其应用
CN116444640A (zh) * 2022-09-26 2023-07-18 昆明医科大学 一种版纳绳蚋抗栓肽Sibanin及其应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0412155A4 (en) 1987-03-27 1991-04-03 Terumo Kabushiki Kaisha Enzyme sensor
EP0965597A4 (en) 1996-12-27 2003-01-08 Mochida Pharm Co Ltd CELL MEMBRANE EFFECTIVE DRUGS

Also Published As

Publication number Publication date
EP1509541A2 (en) 2005-03-02
WO2003103577A2 (en) 2003-12-18
CA2486362A1 (en) 2003-12-18
CN1659180A (zh) 2005-08-24
EP1509541A4 (en) 2006-06-07
AU2003237351A2 (en) 2003-12-22
CN1659180B (zh) 2010-06-02
WO2003103577A3 (en) 2004-03-04
ATE534658T1 (de) 2011-12-15
US20090029444A1 (en) 2009-01-29
JP2005528124A (ja) 2005-09-22
AU2003237351B2 (en) 2009-12-03
US20050164926A1 (en) 2005-07-28
EP1509541B1 (en) 2011-11-23
AU2003237351A1 (en) 2003-12-22
US7378393B2 (en) 2008-05-27

Similar Documents

Publication Publication Date Title
US20090029444A1 (en) Novel recombinant anticoagulant proteins
JP3811186B2 (ja) 線虫から抽出されるセリンプロテアーゼ阻害剤および抗凝固性タンパク質
US5874407A (en) Factor VIIA inhibitors
US5409895A (en) Protease inhibitory polypeptides derived from urinary trypsin inhibitor and compositions thereof
US5876968A (en) Dimer of molecular variant of apolipoprotein and processes for the production thereof
TWI343388B (en) Novel tissue factor targeted thrombomodulin fusion proteins as anticoagulants
JPH09509838A (ja) クニッツドメイン拮抗剤蛋白質
JP2010518039A (ja) カザールタイプ・セリン・プロテアーゼ阻害剤の治療への応用
JPH03255099A (ja) プロテイナーゼ阻害因子、それらの調製方法およびそれらを含有する薬物
JPH05508664A (ja) リン脂質標的血栓溶解剤
EP0866870B1 (en) TISSUE FACTOR - KUNITZ DOMAIN FUSION PROTEINS AS FACTOR VIIa INHIBITORS
JP2000509993A (ja) アポリポタンパク質ｂ―１００由来の抗凝血性ペプチド断片
Chen et al. Fusion proteins comprising annexin V and Kunitz protease inhibitors are highly potent thrombogenic site-directed anticoagulants
US9745363B2 (en) Compositions and methods for inhibiting thrombogenesis
JP2002524076A (ja) ＫｕｎｉｔｚドメインポリペプチドＺＫＵＮ６
JP2009528831A (ja) キメラＫｕｎｉｔｚドメインおよびその使用
WO1990015072A1 (en) Platelet aggregation inhibitors and related molecules
US20060153831A1 (en) Antithrombosis enzyme from the snake venom of Agkistrodon acutus
JP2000503528A (ja) 第ＶＩＩａ因子の新規阻害剤
JP2002515245A (ja) プロテインｚ依存性プロテアーゼインヒビター

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20060605

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20060605

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20090407

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090707

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20090825

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20091118

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20091215

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20100114

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20130122

Year of fee payment: 3

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20130122

Year of fee payment: 3

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees